PSA testing and receipt of curative treatment in elderly Japanese men with prostate cancer: a population-based study.
5 affiliations
- 1Department of Urology, Faculty of Medicine, Saga University, Nabeshima, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan. [email protected].
- 2Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan.
- 3Liver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan.
- 4Occupational Health Data Science Centre, Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahatanishiku, Kitakyushu, 807-8555, Japan.
- 5Department of Urology, Faculty of Medicine, Saga University, Nabeshima, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan.
Abstract
Objective
This study aimed to evaluate whether regular prostate-specific antigen (PSA) testing is associated with the receipt of curative treatment for prostate cancer among men in Japan and to identify associated factors.Methods
A retrospective analysis was conducted using the claims data from the National Health Insurance and Late-Stage Elderly Health Care System in Saga Prefecture between March 2014 and March 2022. Patients were categorized into PSA testing (≥ 1 test ≥ 6 months before treatment) and non-PSA testing groups. Curative treatment was defined as either a radical prostatectomy or carbon-ion radiotherapy. Multivariable logistic regression was used to identify the factors associated with curative treatment.Results
Among 2,200 patients, 737 (33.5%) underwent PSA testing, and 708 (32.2%) received curative treatment. Patients who underwent PSA testing were older and more likely to participate in Specific Health Checkups. The proportion receiving curative treatment was higher in the PSA testing group (36.4% vs. 30.1%, p < 0.001). Age (OR = 0.85), PSA testing (OR = 1.53), and participation in Specific Health Checkups, which do not include PSA testing, were independently associated with curative treatment (OR = 1.64).Conclusions
PSA testing was associated with a higher likelihood of receiving curative treatment for prostate cancer. Participation in Specific Health Checkups may reflect a population more engaged in preventive healthcare or with greater access to screening opportunities.
Related
- Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre
- Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre
- Population‐level diagnostic and radiation treatment trends of low‐risk prostate cancer
- Skin‐Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real‐World Database Study (A Retrospective Cohort Study)
- A solitary brain metastasis from gastroesophageal junction adenocarcinoma 13 years after curative multimodality treatment: a case report and review of the literature
BibTeX
@article{tobu2026testing,
title = {{PSA testing and receipt of curative treatment in elderly Japanese men with prostate cancer: a population-based study.}},
author = {Shohei Tobu and Hirokazu Takahashi and Hiroshi Isoda and Kenji Fujimoto and Mitsuru Noguchi},
journal = {BMC urology},
year = {2026},
month = jul,
doi = {10.1186/s12894-026-02266-3},
url = {https://europepmc.org/article/MED/42919289},
note = {CC BY},
}
RIS
TY - JOUR
TI - PSA testing and receipt of curative treatment in elderly Japanese men with prostate cancer: a population-based study.
AU - Shohei Tobu
AU - Hirokazu Takahashi
AU - Hiroshi Isoda
AU - Kenji Fujimoto
AU - Mitsuru Noguchi
PY - 2026
DA - 2026/07/01
JO - BMC urology
DO - 10.1186/s12894-026-02266-3
UR - https://europepmc.org/article/MED/42919289
AB - Objective This study aimed to evaluate whether regular prostate-specific antigen (PSA) testing is associated with the receipt of curative treatment for prostate cancer among men in Japan and to identify associated factors.Methods A retrospective analysis was conducted using the claims data from the National Health Insurance and Late-Stage Elderly Health Care System in Saga Prefecture between March 2014 and March 2022. Patients were categorized into PSA testing (≥ 1 test ≥ 6 months before treatment) and non-PSA testing groups. Curative treatment was defined as either a radical prostatectomy or carbon-ion radiotherapy. Multivariable logistic regression was used to identify the factors associated with curative treatment.Results Among 2,200 patients, 737 (33.5%) underwent PSA testing, and 708 (32.2%) received curative treatment. Patients who underwent PSA testing were older and more likely to participate in Specific Health Checkups. The proportion receiving curative treatment was higher in the PSA testing group (36.4% vs. 30.1%, p < 0.001). Age (OR = 0.85), PSA testing (OR = 1.53), and participation in Specific Health Checkups, which do not include PSA testing, were independently associated with curative treatment (OR = 1.64).Conclusions PSA testing was associated with a higher likelihood of receiving curative treatment for prostate cancer. Participation in Specific Health Checkups may reflect a population more engaged in preventive healthcare or with greater access to screening opportunities.
SN - 1471-2490
ER -